AMY SCHEFLER to Angiogenesis Inhibitors
This is a "connection" page, showing publications AMY SCHEFLER has written about Angiogenesis Inhibitors.
Connection Strength
1.113
-
ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTIONS DURING THE COVID-19 PANDEMIC WITH IMPLEMENTATION OF UNIVERSAL MASKING. Retina. 2021 11 01; 41(11):2208-2214.
Score: 0.465
-
Randomized Trial of Monthly Versus As-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1-Year Outcomes. Am J Ophthalmol. 2020 08; 216:165-173.
Score: 0.418
-
Morphological Biomarkers Related to Visual Acuity in Patients With Radiation Retinopathy Treated With Intravitreal Ranibizumab. Ophthalmic Surg Lasers Imaging Retina. 2024 May; 55(5):255-262.
Score: 0.137
-
Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes. Invest Ophthalmol Vis Sci. 2023 Jun 01; 64(7):35.
Score: 0.032
-
Two-year results for ranibizumab for radiation retinopathy (RRR): a randomized, prospective trial. Graefes Arch Clin Exp Ophthalmol. 2022 Jan; 260(1):47-54.
Score: 0.029
-
ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: Role of Prophylactic Topical Ophthalmic Antibiotics. Retina. 2016 Jul; 36(7):1349-56.
Score: 0.020
-
Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment. Invest Ophthalmol Vis Sci. 2009 Mar; 50(3):1020-4.
Score: 0.012